

Experienced management team which have significant clinical development expertise





Dr Mark Marino
SAN DIEGO, USA
Chief Medical Officer

- 28+ years of experience in drug development
- Former CMO of Cytori, Head of Clinical Pharmacology at Eisai and Roche, Head of R&D at Mannkind and VP Clinical Development at Daiichi



Dr Nick EdeMELBOURNE, AU

Chief Technology Officer

- 25+ years peptide vaccine and drug development
- Former CEO Adistem and CEO of Mimotopes, VP Chemistry Chiron (now Novartis), Research Fellow CRC Vaccine Technology



Dr Anthony GoodSYDNEY, AU

VP of Clinical Research

- 20+ years experience in global clinical development
- Integral to the development of significant new medicines including Viagra, Revatio, Lipitor, and Somavert
- Ex Pfizer Global Research and Development, Ex Covance Clinical Services



Bonnie Nixon SYDNEY, AU Project Manager

- 5+ years of oncology experience across Phase I IV clinical trials
- Ex North America Study Manager at Genentech, Ex Roche Clinical Operations Australia

2018 - 2019 Year in Review




- Successful integration of Ohio Sate University B Cell immunotherapies
- Commencement of PD-1 manufacturing
- Successful Pre-IND FDA meeting for guidance for PD1-Vaxx Clinical Development Plan
- Met endpoints in Phase 1B HER-Vaxx gastric study
- First Patient Dosed in HER-Vaxx Phase 2 Study
- Leading international life science experts join the IMU Board : Dr. Russell and Dr. Eckstein
- Scientific Advisory Board (SAB) enhanced with appointments of Professors Kaumaya, Saab, & Caligiuri
- Proposed acquisition of City of Hope CF33 oncolytic virus
- Proposed new OV SAB to be Chaired by Prof Yuman Fong

HER-Vaxx PUBLICATIONS in MAJOR CANCER CONFERENCES




AACR



AACR 2019

A Phase Ib open label multicenter study with a HER2/neu peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy shows safety, immunogenicity and clinical response in patients with HER2/neu overexpressing advanced cancer of the stomach


ESMO-GI



ESMO-GI 2019

A Phase 1B study of IMU-131 HER2/NEU peptide vaccine plus chemotherapy in patients with HER2/NEU overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction


ASCO



ASCO 2019

A Phase 1b study of IMU-131 HER2/NEU peptide vaccine plus chemotherapy in patients with HER2/NEU overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction

ESMO




ESMO-2019

Comprehensive results of a Phase Ib study with a HER2/neu B-cell peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy show safety, immunogenicity and clinical response in patients with HER2/neu overexpressing advanced gastric cancer

PD1-Vaxx PUBLICATIONS MAJOR CANCER CONFERENCES




AACR



AACR 2019

Development of a novel PD-1 vaccine and in combination with two Chimeric HER-2 peptide vaccine provides synergistic inhibition of tumor growth in a syngeneic Balb/c model challenged with CT26/HER-2 carcinoma cell line

ESMO



ESM0-2019

Antitumor activity and safety of a novel PD-1 vaccine (PD1-Vaxx) alone and in combination with two chimeric HER-2 peptide vaccine (B-Vaxx) in syngeneic Balb/c mice and canines

Proposed Vaxinia CF33 Oncolytic Virus (OV) Acquisition iMUGENE




- OVs are a promising area of immuno-oncology and of focused interest to Big Pharma
- Vaxinia offers IMU the opportunity of entering the OV field at a relatively advanced stage of development
- Two clinical trials are forecast to commence in 2020: one at City of Hope and the other across multiple centres in the U.S.
- One GMP virus lot completed; the other is near final in completion.
- The inventor Professor Yuman Fong is an internationally recognized surgeon, a researcher, a scholar, a true renaissance man.
- The acquisition of Vaxinia brings with it the core experienced clinical development team of Viralyics – which sold to Merck last year for A\$502 million






CF33 MANAGEMENT TEAM





MULTIPLE NEAR & MEDIUM TERM VALUE INFLECTION POINTS





Next 12 months

Financial Summary




Public Market Overview

A\$83.1M
MAO2.TIVI
A\$17.8M
A\$65.3M

1 of 5 similars (as at 5 to 5	
National Nominees Limited	5.6%
Dr. Nicholas Smith	3.3%
Paul Hopper	2.1%
HSBC Custody Nominees (Australia)	1.8%
Sarah Cameron	1.7%

Note:

Share Price Performance (last 6 months)



^{1.} As of 29 October 2019

^{2.} Market capitalization calculations based on ordinary shares (3.61bn) only and excludes the dilutive impact of options outstanding (652m)

